Zacks Analyst Blog Highlights: Schering-Plough, Merck, CNOOC and Sinopec.CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Schering-Plough (NYSE NYSE See: New York Stock Exchange : SGP SGP Singapore (ISO Country code) SGP Schering-Plough (stock symbol) SGP Stability and Growth Pact SGP Southern Great Plains SGP Staatkundig Gereformeerde Partij SGP Speedway Grand Prix ), Merck (NYSE: MRK MRK Merck & Company (stock symbol) MRK Mayer-Rokitansky-Kuster (anomaly) MRK Manual Remote Keying ), CNOOC CNOOC China National Offshore Oil Corporation (NYSE: CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. ) and Sinopec (NYSE: SNP). See the latest posts to the Analyst Blog by visiting: http://at.zacks.com/?id=2673 Here are highlights from Thursday's Analyst Blog: Turnaround is Complete at SGP Schering-Plough (NYSE: SGP) is engaged in the development, manufacturing and marketing of pharmaceutical products around the world. The company focuses on prescription drugs, animal health, foot-care and sun-care products. Lead products include its antihistamine antihistamine (ăn'tĭhĭs`təmēn), any one of a group of compounds having various chemical structures and characterized by the ability to antagonize the effects of histamine. franchise Claritin/Clarinex and a cholesterol-lowering joint-venture therapy treatment (Vytorin) with Merck (NYSE: MRK). The turnaround is complete at SGP. The company should deliver the highest four-year earnings growth rate in the large-cap pharmaceutical industry. Valuation becomes attractive based on recovery EPS (Encapsulated PostScript) A PostScript file format used to transfer a graphic image between applications and platforms. EPS files contain PostScript code as well as an optional preview image in TIFF, WMF, PICT or EPSI, the latter being an ASCII-only format. [earnings per share] in 2008 and 2009. The company recently announced it will acquire Organon Bio for $14.4 billion in cash/debt/equity. We recommend investors buy the name up to $28. Expect PTR to Trade With Market Zacks senior Chinese market analyst Paul Cheung, CFA (Computer Fraud and Abuse Act of 1986) Signed into law in 1986, the CFA was a significant step forward in criminalizing unauthorized access to computer systems and networks. The Act applies to "federal interest computers" that include any system used by the U.S. retains his Hold recommendation on shares of PetroChina (NYSE: PTR), even though the shares have pulled back from their highs around the beginning of the year. We looked into his recent research report to find some details: While PetroChina's results continue to benefit from high oil prices and strong domestic demand, the company's long-term growth prospects remain uncertain. Given the maturity of its domestic upstream asset base, international acquisitions appear to be the only growth avenue open to the company. PetroChina faces a number of challenges in executing this strategy, including high asset prices due to continued strength in commodity prices and intense global competition for upstream assets. Thus, we maintain our Hold rating for PTR ADRs [American Depositary Shares]. Based on our estimate for fiscal year 2007 earnings per ADR ADR - Astra Digital Radio , the company is trading at 9.9x, which is slightly lower than the industry mean. Compared with its local peers, its P/E P/E See: Price/earnings ratio [price-to-earnings] is similar to that of CNOOC (NYSE: CEO) and Sinopec (NYSE: SNP). Thus, we believe current valuation fairly represents its fair value. Using a P/E multiple of 10.4x our fiscal year 2007 earnings per ADR estimate of $11.11 yields a target price of $116.00, which we believe reflects the company's prospects. See the latest posts to the Analyst Blog by visiting http://at.zacks.com/?id=2645 About Zacks Equity Research Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term. Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons. Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2674. About Zacks Zacks.com is a property of Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. , Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion